{"classes":[{"categories":[{"measurements":[{"comment":"Too few events have occurred to estimate the median and upper 95% confidence interval.","groupId":"OG000","lowerLimit":"4.3","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"Overall Survival (OS) is defined as the time from Stem Cell Transplant (SCT) to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 400 mg sonidegib PO QD on days 1-28 and 10 mg lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Sonidegib, Lenalidomide)"}],"paramType":"MEDIAN","populationDescription":"All patients that began protocol treatment and were eligible were included in this endpoint.","reportingStatus":"POSTED","timeFrame":"Time from SCT to death due to any cause, assessed up to 3 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"years"}